← Russell 3000 cross-section

CCCC C4 Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$527m
Revenue TTM
$35m
Net income TTM
$-101m
Free cash flow
$-85m
Composite score
33.1
Sector rank
#2378

Valuation

P / E
EV / EBITDA
EV / sales
12.8
FCF yield
-16.22%
Earnings yield vs 10-yr
-23.99pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-289.4%
EBITDA margin
-314.6%
ROE
-41.0%
ROIC
-66.3%
Revenue growth
2.3%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

To date, the Company has funded its operations primarily with proceeds received from the sales of redeemable convertible preferred stock, public offerings of the Company’s common stock, private placements of the Company's common stock, debt financing, and through its collaboration agreements. As part of the collaboration, Betta Pharma made an upfront cash payment of $ 10.0 million to the Company and has agreed to make up to $ 357.0 million in aggregate milestone payments, plus tiered royalties on net sales of CFT8919 in Greater China. …C4 Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →